Full text is available at the source.
Abstract
Tirzepatide may reduce cardiorenal biomarkers and improve functional capacity in patients with heart failure and obesity.
- Tirzepatide is associated with clinical benefits in heart failure with preserved ejection fraction (HFpEF) and obesity.
- Significant reductions in cardiorenal biomarkers may occur with tirzepatide treatment.
- Improvements in functional capacity could be observed with tirzepatide compared to placebo or standard care.
Simplified